Cargando…

Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen?

BACKGROUND: Recurrent vulvovaginal candidiasis (RVVC) is a common cause of morbidity affecting millions of women worldwide. Patients with RVVC are thought to have an underlying immunologic defect. This study has been established to evaluate cell-mediated immunity defect in response to candida antige...

Descripción completa

Detalles Bibliográficos
Autores principales: Talaei, Zahra, Sheikhbahaei, Saba, Ostadi, Vajihe, Ganjalikhani Hakemi, Mazdak, Meidani, Mohsen, Naghshineh, Elham, Yaran, Majid, Naeini, Alireza Emami, Sherkat, Roya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royan Institute 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582140/
https://www.ncbi.nlm.nih.gov/pubmed/28868834
_version_ 1783261131040620544
author Talaei, Zahra
Sheikhbahaei, Saba
Ostadi, Vajihe
Ganjalikhani Hakemi, Mazdak
Meidani, Mohsen
Naghshineh, Elham
Yaran, Majid
Naeini, Alireza Emami
Sherkat, Roya
author_facet Talaei, Zahra
Sheikhbahaei, Saba
Ostadi, Vajihe
Ganjalikhani Hakemi, Mazdak
Meidani, Mohsen
Naghshineh, Elham
Yaran, Majid
Naeini, Alireza Emami
Sherkat, Roya
author_sort Talaei, Zahra
collection PubMed
description BACKGROUND: Recurrent vulvovaginal candidiasis (RVVC) is a common cause of morbidity affecting millions of women worldwide. Patients with RVVC are thought to have an underlying immunologic defect. This study has been established to evaluate cell-mediated immunity defect in response to candida antigen in RVVC cases. MATERIALS AND METHODS: Our cross-sectional study was performed in 3 groups of RVVC patients (cases), healthy individuals (control I) and known cases of chronic mucocutaneous candidiasis (CMC) (control II). Patients who met the inclusion criteria of RVVC were selected consecutively and were allocated in the case group. Peripheral blood mononuclear cells were isolated and labeled with CFSE and proliferation rate was measured in exposure to candida antigen via flow cytometry. RESULTS: T lymphocyte proliferation in response to candida was significantly lower in RVVC cases (n=24) and CMC patients (n=7) compared to healthy individuals (n=20, P<0.001), but no statistically significant difference was seen between cases and control II group (P>0.05). Family history of primary immunodeficiency diseases (PID) differed significantly among groups (P=0.01), RVVC patients has family history of PID more than control I (29.2 vs. 0%, P=0.008) but not statistically different from CMC patients (29.2 vs. 42.9%, P>0.05). Prevalence of atopy was greater in RVVC cases compared to healthy individuals (41.3 vs. 15%, P=0.054). Lymphoproliferative activity and vaginal symptoms were significantly different among RVVC cases with and without allergy (P=0.01, P=0.02). CONCLUSION: Our findings revealed that T cells do not actively proliferate in response to Candida antigen in some RVVC cases. So it is concluded that patients with cell-mediated immunity defect are more susceptible to recurrent fungal infections of vulva and vagina. Nonetheless, some other cases of RVVC showed normal function of T cells. Further evaluations showed that these patients suffer from atopy. It is hypothesized that higher frequency of VVC in patients with history of atopy might be due to allergic response in mucocutaneous membranes rather than a functional impairment in immune system components.
format Online
Article
Text
id pubmed-5582140
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Royan Institute
record_format MEDLINE/PubMed
spelling pubmed-55821402017-10-01 Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen? Talaei, Zahra Sheikhbahaei, Saba Ostadi, Vajihe Ganjalikhani Hakemi, Mazdak Meidani, Mohsen Naghshineh, Elham Yaran, Majid Naeini, Alireza Emami Sherkat, Roya Int J Fertil Steril Original Article BACKGROUND: Recurrent vulvovaginal candidiasis (RVVC) is a common cause of morbidity affecting millions of women worldwide. Patients with RVVC are thought to have an underlying immunologic defect. This study has been established to evaluate cell-mediated immunity defect in response to candida antigen in RVVC cases. MATERIALS AND METHODS: Our cross-sectional study was performed in 3 groups of RVVC patients (cases), healthy individuals (control I) and known cases of chronic mucocutaneous candidiasis (CMC) (control II). Patients who met the inclusion criteria of RVVC were selected consecutively and were allocated in the case group. Peripheral blood mononuclear cells were isolated and labeled with CFSE and proliferation rate was measured in exposure to candida antigen via flow cytometry. RESULTS: T lymphocyte proliferation in response to candida was significantly lower in RVVC cases (n=24) and CMC patients (n=7) compared to healthy individuals (n=20, P<0.001), but no statistically significant difference was seen between cases and control II group (P>0.05). Family history of primary immunodeficiency diseases (PID) differed significantly among groups (P=0.01), RVVC patients has family history of PID more than control I (29.2 vs. 0%, P=0.008) but not statistically different from CMC patients (29.2 vs. 42.9%, P>0.05). Prevalence of atopy was greater in RVVC cases compared to healthy individuals (41.3 vs. 15%, P=0.054). Lymphoproliferative activity and vaginal symptoms were significantly different among RVVC cases with and without allergy (P=0.01, P=0.02). CONCLUSION: Our findings revealed that T cells do not actively proliferate in response to Candida antigen in some RVVC cases. So it is concluded that patients with cell-mediated immunity defect are more susceptible to recurrent fungal infections of vulva and vagina. Nonetheless, some other cases of RVVC showed normal function of T cells. Further evaluations showed that these patients suffer from atopy. It is hypothesized that higher frequency of VVC in patients with history of atopy might be due to allergic response in mucocutaneous membranes rather than a functional impairment in immune system components. Royan Institute 2017 2017-09-03 /pmc/articles/PMC5582140/ /pubmed/28868834 Text en Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Talaei, Zahra
Sheikhbahaei, Saba
Ostadi, Vajihe
Ganjalikhani Hakemi, Mazdak
Meidani, Mohsen
Naghshineh, Elham
Yaran, Majid
Naeini, Alireza Emami
Sherkat, Roya
Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen?
title Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen?
title_full Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen?
title_fullStr Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen?
title_full_unstemmed Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen?
title_short Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen?
title_sort recurrent vulvovaginal candidiasis: could it be related to cell-mediated immunity defect in response to candida antigen?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582140/
https://www.ncbi.nlm.nih.gov/pubmed/28868834
work_keys_str_mv AT talaeizahra recurrentvulvovaginalcandidiasiscoulditberelatedtocellmediatedimmunitydefectinresponsetocandidaantigen
AT sheikhbahaeisaba recurrentvulvovaginalcandidiasiscoulditberelatedtocellmediatedimmunitydefectinresponsetocandidaantigen
AT ostadivajihe recurrentvulvovaginalcandidiasiscoulditberelatedtocellmediatedimmunitydefectinresponsetocandidaantigen
AT ganjalikhanihakemimazdak recurrentvulvovaginalcandidiasiscoulditberelatedtocellmediatedimmunitydefectinresponsetocandidaantigen
AT meidanimohsen recurrentvulvovaginalcandidiasiscoulditberelatedtocellmediatedimmunitydefectinresponsetocandidaantigen
AT naghshinehelham recurrentvulvovaginalcandidiasiscoulditberelatedtocellmediatedimmunitydefectinresponsetocandidaantigen
AT yaranmajid recurrentvulvovaginalcandidiasiscoulditberelatedtocellmediatedimmunitydefectinresponsetocandidaantigen
AT naeinialirezaemami recurrentvulvovaginalcandidiasiscoulditberelatedtocellmediatedimmunitydefectinresponsetocandidaantigen
AT sherkatroya recurrentvulvovaginalcandidiasiscoulditberelatedtocellmediatedimmunitydefectinresponsetocandidaantigen